Cardioprotective Properties of Omecamtiv Mecarbil against Ischemia and Reperfusion Injury

Omecamtiv mecarbil (OM) is a first-in-class myosin activator. It was developed as a new inotropic therapy option for heart failure and is currently the object of a phase 3 clinical trial program. OM activates ryanodine receptors, which were shown to be involved in cardioprotection induced by conditi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Med
Autori principali: Stroethoff, Martin, Behmenburg, Friederike, Meierkord, Simon, Bunte, Sebastian, Mayer, Felix, Mathes, Alexander, Heinen, André, Hollmann, Markus W., Huhn, Ragnar
Natura: Artigo
Lingua:Inglês
Pubblicazione: MDPI 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6463149/
https://ncbi.nlm.nih.gov/pubmed/30889854
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm8030375
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi